+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the performance of two blood-based diagnostic aid tests designed to detect cancer in individuals aged 45 and older who show symptoms, signs, or findings that suggest possible cancer. The study focuses on cancers originating from specific sites as outlined in the protocol, aiming to establish how well these tests identify the presence of cancer compared to standard diagnostic methods. Participants will provide a blood sample for analysis by the investigational diagnostic tests. The study includes people either undergoing diagnostic work-up for suspected cancer or those recently diagnosed with cancer who have not yet received treatment. The test results will be kept blinded from investigators, clinicians, and participants, ensuring that the investigational test does not influence clinical decisions. All analyses will be done without revealing results during the study period. During the study, participants will have blood collected and undergo standard diagnostic procedures as recommended by their doctors. The research team will gather clinical outcomes based on routine care diagnostics and pathology reports. Researchers will measure how accurately the tests detect cancer and assess various test readout distributions over an 18-month period. Participants involvement includes consenting to blood draws and allowing access to diagnostic information, with no additional interventions affecting their usual care.

Age: 45Years +All Genders
42 locations
E

Actively Recruiting

Healthy Volunteer

This research aims to evaluate the Shield blood tests performance for colorectal cancer CRC screening in people aged 45 to 81 who are at average risk for CRC. The study focuses on assessing the test during a second round of screening, using colonoscopy as the reference standard. CRC is a common and serious disease, especially affecting older adults and certain minority groups, with early detection being key to improving outcomes. Participants will undergo the Shield blood test as part of their routine standard care, and their results will be compared to colonoscopy findings. This study is observational and collects real-world evidence over a period of 33 to 42 months after enrollment to assess how well the Shield test performs in detecting CRC or its precursors during the second screening interval. Participants will be involved in scheduled study procedures and standard care assessments, with data collected on the tests accuracy and effectiveness over time. The main outcome measured is the performance of the Shield test during the second testing period. The study will continue until December 2030, monitoring participants to gather long-term information about CRC screening efficacy in an average-risk population.

Age: 45Years - 81YearsAll Genders
69 locations